A Systematic Overview of Chemotherapy Effects in Aggressive non-Hodgkin's Lymphoma

References

• Harris LH, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994; 84: 1361-92. (L1)
   PubMedGoogle Scholar
• Lennert K, Feller A. Histopathology of non-Hodgkin's lymphomas, ed. 2. New York: Springer-Verlag, 1992. (01)
   Google Scholar
• Pittaluga S, Bijnens L, Teodorovic I, et al. Clinical analysis of 777 NHL cases subtyped according to the Revised Eu-ropean-American Classification: an EORTC lymphoma group study. Proc Am Soc Hematol 1995; 86: Abstr 24H. (R3/777)
   Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classifica-tion - from controversy to consensus: The R.E.A.L. and WHO classifications of lymphoid neoplasms. Ann Oncol 2000; 11 (Suppl 1): 3–10.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6. (L 1)
   Google Scholar
• The International non-Hodgkin's lymphoma prognostic fac-tors project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-94. (R1/2031)
   Google Scholar
• Gordon LI, Andersen J, Colgan J, et al. Advanced diffuse non-Hodgkin's lymphoma: Analysis of prognostic factors by the International Index and by lactic dehydrogenase in an intergroup study. Cancer 1995; 75: 865-73. (R2/392)
   Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxy-daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-93. (C2/104)
   Google Scholar
• Working Formulation. The non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma: summary and description of a working formula-tion for clinical use. Cancer 1982; 49: 158-81. (R1/1175)
   Google Scholar
• Hagberg H, Pettersson U, Glimelius B, et al. Prognostic factors in non-Hodgkin's lymphoma stage I treated with radiotherapy. Acta Oncol 1989; 28: 45-50. (R2/166)
   Google Scholar
• Hudson BV, Hudson GV, MacLennan KA, et al. Clinical stage I non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investi-gation with radiotherapy alone as initial therapy. Br J Can-cer 1994; 69: 1088–93. (R1/243 high-grade 208 low-grade)
   PubMedGoogle Scholar
• SBU - The Swedish Council on Technology Assessment in Health Care. Non-Hodgkin's lymphomas (NHL). Acta Oncol 1996; 2 (Suppl 7): 102–22.
   Google Scholar
• Jones SE, Miller T, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemother-apy with or without adjuvant radiotherapy. J Clin Oncol 1989; 7: 1186-91. (P1/142)
   Google Scholar
• Osterman B, Hagberg H, Lenner P, et al. High-grade malig-nant non-Hodgkin's lymphoma stage I. Acta Oncol 1996; 10: 171-7. (R1/213)
   Google Scholar
• Connors JM, Klimo P, Fairey RN, et al. Brief chemotherapy and involved field radiation therapy for limited-stage histo-logically aggressive lymphoma. Ann Intern Med 1987; 107: 30-5. (P1/78)
   Google Scholar
• Tondini CT, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy fol-lowed by locoregional irradiation in stage I or II histologi-cally aggressive non-Hodgkin's lymphomas. J Clin Oncol 1993; 11: 720-5. (P2/183)
   Google Scholar
• Longo DL. Combined modality therapy for localized aggres-sive lymphoma: Enough or too much. J Clin Oncol 1989; 7: 1179-81. (P2/47)
   Google Scholar
• Van der Maazen RW, Noordijk EM, Thomas J, et al. Combined modality treatment is the treatment of choice for stage 1/1E intermediate and high grade non-Hodgkin's lymphomas. Radiother Oncol 1998; 49: 1–7.
   PubMed Web of Science ®Google Scholar
• Yahalom J, Varsos G, Fuks Z, et al. Adjuvant cyclophos-phamide, doxorubicin, vincristine and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin's lymphoma. Cancer 1993; 71: 2342-50. (C3/44)
   Google Scholar
• Aviles A, Delgado S, Ruis H, et al. Treatment of non-Hodgkin's lymphoma of Waldayer's ring. Eur J Cancer 1996; 32: 19-23. (C2/316)
   Google Scholar
• Glick JM, Kim K, Earle J, et al. An ECOG randomised phase I and 11 trial of CHOP vs CHOP ± radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma, Proc Am Soc Clin Oncol 1995; 14: Abstr 1221. (C3/345)
   Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high grade non-Hodgkin's lymphoma. New Engl J Med 1998; 339: 21-6. (C1/401)
   Google Scholar
• Landberg T, Hakansson L, Moller T, et al. CVP-remission in stage I or 11 non-Hodgkin's lymphoma. Cancer 1979; 44: 831-8. (C3/55)
   Google Scholar
• Monfardini S, Bandi A, Bonnadonna G, et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-11 non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1980; 6: 125-34. (C2/96)
   Google Scholar
• Nissen NI, Ersböll J, Hansen S, et al. A randomised study of radiotherapy vs radiotherapy plus chemotherapy in stage I-11 non-Hodgkin's lymphoma. Cancer 1983; 52: 1-7. (C2/73)
   Google Scholar
• Coltman CA, Dahlberg S, Jones SE. CHOP is curative in thirty% of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: Skarin AT, ed. Adv Cancer Chemotherapy. New York: Park Row, 1986: 71–8. (L1)
   Google Scholar
• Fisher RI, De Vita Jr VT, Hubbard SM, et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304-9. (P3/74)
   Google Scholar
• Klimo P, Connors JM. MACOP-B chemotherapy for treat-ment of diffuse large-cell lymphoma. Ann Int Med 1985; 102: 596-602. (R2/61)
   Google Scholar
• Skarin AT, Cannellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91-8. (P3/101)
   Google Scholar
• Goldie JA, Coldman AJ. The genetic origin of drug resis-tance in neoplasma implication for systemic therapy. Cancer Res 1982; 44: 3643-53. (01)
   Google Scholar
• Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 pro-tocol. Ann Oncol 1993; 4: 651-6. (R2/311)
   Google Scholar
• Kwak LW, Halpern J, Ohlsen RA, et al. Prognostic signifi-cance of actual dose intensity in diffuse large-cell lymphoma: Results of a three-structured survival analysis. J Clin Oncol 1990; 8: 963-77. (R3/115)
   Google Scholar
• Shipp MA, Neuberg D, Janiceck M, et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose finding pilot study. J Clin Oncol 1995; 13: 2916-23. (P3/30)
   Google Scholar
• Coiffier B. Fourteen years of high-dose CHOP (ACVB regi-men): Preliminary conclusions about the treatment of ag-gressive-lymphoma patients. Ann Oncol 1995; 6: 211-7. (P1/3000)
   Google Scholar
• Meyer RM, Quirt IC, Skillings JR, et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 1770-6. (C2/204)
   Google Scholar
• Hagberg H, Lindemalm C, Cavallin-Stal E. CHOP vs CHOP-M in the treatment of high-grade malignant non-Hodgkin's lymphoma in adults, Proc Am Soc Clin Oncol 1988; 7: Abstr 942. (C3/204)
   Google Scholar
• Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New Engl J Med 1992; 327: 1342-9. (C1/325)
   Google Scholar
• Carde P, Meerwaldt JH, van Glabbeke M, et al. Superiority of second over first-generation chemotherapy in a ran-domised trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): The 1980-1985 EORTC trial. Ann Oncol 1991; 2: 431-5. (C2/141)
   Google Scholar
• Meerwaldt JH, Carde P, Somers R, et al. Persistent im-proved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone com-bination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: 67-70. (C2/141)
   Google Scholar
• O'Reilly SE, Hoskins P, Klimo P, et al. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2 (Suppl 1): 17–23. (P2/126 ± 108)
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemother-apy regimens for advanced diffuse non-Hodgkin's lymphoma. New Engl J Med 1993; 327: 1342-9. (C1/ 899)
   Google Scholar
• Wolf MM, Cooper IA, Robertsson TI, et al. Randomised comparison of MACOP-B with CHOP for patients with intermediate-grade non-Hodgkin's lymphoma: long-term fol-low-up. Ann Oncol 1997; (Suppl 1): 71–5. (C1/305)
   Google Scholar
• Jerkeman M, Anderson H, Cavallin-Stahl E, et al. CHOP vs MACOP-B in aggressive lymphoma-A Nordic Lymphoma Group randomised trial. Ann Oncol 1999; 10: 1079-86. (C1/405)
   Google Scholar
• Sertoli MR, Santini G, Chisesi T, et al. MACOP-B vs ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: The result of a prospective ran-domised trial by the non-Hodgkin's lymphoma cooperative group. J Clin Oncol 1994; 12: 1366-74. (C2/221)
   Google Scholar
• Linch DC, Hudson V, Hudson V, et al. PACEBOM is superior to CHOP in patients with stage IV histologically aggressive non-Hodgkin's lymphoma (NHL): Results of a British National Lymphoma Investigation (BNLI) trial. Br J Hematol 1996; 74: 318-22. (C1/459)
   Google Scholar
• Linch DC, Smit P, Hancock BW, et al. A randomised British National Lymphoma Investigation trial of CHOP vs a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11 (Suppl 1): 87–90. (C1/459)
   Google Scholar
• Bailey NP, Stuart NS, Bessell EM, et al. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) vs cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 633-8. (C1/381)
   Google Scholar
• Montserrat E, Garcia-Conde J, Vinolas N, et al. CHOP vs ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. Eur J Haematol 1996; 57: 377-83. (C2/ 175)
   Google Scholar
• Koppler H, Pfluger KH, Eschenbach I, et al. Randomised comparison of CHOEP vs alternating hCHOEP/IVEP for high-grade non-Hodgkin's lymphoma: Treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol 1994; 5: 49-55. (C2/171)
   Google Scholar
• Bergmann L, Karakas T, Knuth A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma-a randomised pilot study. Eur J Cancer 1995; 31: 2164-8. (C3/ 35)
   Google Scholar
• Gerhartz HH, Engelhard M, Meusers P, et al. Randomised, double-blind, placebo-controlled, phase III study of recom-binant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malig-nant non-Hodgkin's lymphomas. Blood 1993; 82: 2329-39. (C3/182)
   Google Scholar
• Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-con-trolled phase IIII study of lenograstim (glycosylated recom-binant granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma influencing chemotherapy admin-istration. Leuk Lymphoma 1997; 25: 289-300. (C2/162)
   Google Scholar
• Pettengell R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomised controlled trial . Blood 1992; 80: 1430-6. (C2/80)
   Google Scholar
• Boyd DB, Coleman M, Papish SW, et al. COPBLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 425-33. (P3/51)
   Google Scholar
• Sparano JA, Wiernik PH, Leaf A, et al. Infusional cy-clophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071-9. (P2/68)
   Google Scholar
• Wilson WH, Bryant G, Bates S, et al. EPOCH chemother-apy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-82. (P1/74)
   Google Scholar
• Khaled HM, Zekri Z, Mokhttar NM, et al., EPOCH vs CHOP as front line therapy for aggressive non-Hodgkin's lymphoma patients: a randomised trial, Proc Am Soc Clin Oncol 1997; Abstr 81. (C3/78)
   Google Scholar
• Hoskins P, Le N, Gascoyne RD, et al. Advanced diffuse large cell lymphoma treated with a 12-week combination chemotherapy: Natural history of relapse after initial com-plete remission and prognostic variables defining outcome after relapse. Ann Oncol 1997; 8: 1125-32. (R1/468)
   Google Scholar
• Enblad G, Glimelius B, Hagberg H, et al. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. Acta Oncol 1990; 29: 297-301. (P2 /47)
   Google Scholar
• Enblad G, Hagberg H, Glimelius B. Methyl-GAG, ifos-famide, methotrexate and etoposide (MIME) as salvage ther-apy for non-Hodgkin's lymphomas. A Swedish prospective study. Acta Oncol 1996; 35: 165-70. (P1/75)
   Google Scholar
• Bezwoda WR, Bezwoda MA, Seymour L, et al. NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma. Leuk Lymphoma 1993; 10: 329-33. (P2/43)
   Google Scholar
• Cabanillas FB, Rodriguez V, Bodey GP. Ifosfamide, Methotrexate and Vincristine (IMV) combination chemotherapy as secondary treatment for patients with ma-lignant lymphoma. Cancer Treat Rep 1980; 64: 933-7. (P2/ 32)
   Google Scholar
• Cabanillas F, Hagemeister FB, Bodey GP, et al. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693-7. (P2/52)
   Google Scholar
• Cabanillas F, Hagemeister F, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-12. (P1/208)
   Google Scholar
• Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): An effec-tive and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990; 76: 1293-8. (P2/61)
   Google Scholar
• De Lord C, Newland AC, Linch DC, et al. Failure of EVIVP16 as second line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Haematol Oncol 1992; 10: 81-6. (P2/ 46)
   Google Scholar
• Dufour P, Mors R, Berthaud P, et al. Idarubicin and high dose Cytarabine: A new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 22: 329-34. (P2/28)
   Google Scholar
• Goss P, Shepherd F, Scott JG, et al. DICE (Dexamethasone, Ifosfamide, Cisplatin, Etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma 1995; 18: 123-9. (P1/36)
   Google Scholar
• Heinz R, Dittric H, Ludwig H, et al. Results of a new drug combination(VP-16-Ifosfamide-Mitoxantrone-Bleomycin(VIM-BLEO) in advanced non-Hodgkin's lymphomas. Contr Oncol (Karger Basel) 1987; 26: 438-45. (P2/30)
   Google Scholar
• Herbrecht R, Garcia JJ, Bergerat JP, et al. VP-16, ifos-famide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen. Cancer Chemother Pharmacol 1989; 24: 338-9. (P3/20)
   Google Scholar
• Herbrecht R, Ortiz S, Damonte J, et al. Etoposide, ifos-famide and methotrexate combination chemotherapy in pa-tients with aggressive non-Hodgkin's lymhoma after failure of the LNH 84 regimen. Hematol Oncol 1991; 8: 253-7. (P3/19)
   Google Scholar
• Merk K, Idestrom K, Johansson B, et al. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin's lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. Eur J Haematol 1991; 46: 33-7. (P2/26)
   Google Scholar
• Miller T, Grogan T, Dalton W, et al. P-glycoprotein expres-sion in malignant lymphoma and reversal of clincial drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17-24. (P3/18)
   Google Scholar
• Neidhart JA, Kubica R, Stidley C, et al. Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma. Cancer Invest 1994; 12: 1-11. (P3/26)
   Google Scholar
• Nowrousian MR, Anders CH, Niederle N, et al. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. Ann Oncol 1991; 2 (Suppl 1): 25–30. (P2/28)
   Google Scholar
• Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-41. (P1/92)
   Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-22. (P2/90)
   Google Scholar
• Velasquez WS, Mc Laughlin P, Tucker S, et al. ESHAP - An effective chemotherapy regimen in refractory and relaps-ing lymphoma: A 4-year follow-up study. J Clin Oncol. 1992; 12: 1169-76. (P1/122)
   Google Scholar
• Warrell RP, Danieu L, Coonley CJ, et al. Salvage chemotherapy of advanced lymphoma with investigational drugs: Mitoguazone, Gallium Nitrate, and Etoposide. Can-cer Treat Rep 1987; 71: 47-51. (P1/42)
   Google Scholar
• Jackson GH, Lennard AL, Taylor PR, et al. On behalf of the Newcastle & Northern Lymphoma Group. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Br J Can-cer 1994; 70: 501–5. (P2/128, 30 transplanted)
   Google Scholar
• Nademanee A, Schmidt GH, O'Donell MR. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first com-plete remission in adult patients with poor risk aggressive lymphoma. Blood 1992; 80: 1130-4. (P3/20)
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation (ABMT) with se-quential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994; 12: 2543-51. (C1/464)
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation (ABMT) over se-quential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma (NHL). J Clin Oncol 1997; 15: 1131–7. (C3/236 'high risk', subgroup analysis of totally 542 patients)
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A GELA study, Blood 1999;(Suppl): Abstr 2711. (C3/236)
   Google Scholar
• Santini G, Salvagno L, Leoni P, et al. VACOP-B vs VA-COP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomised trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796-802. (C2/124)
   Google Scholar
• Vitoli U, Cortelazzo S, Liberati AM, et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulat-ing factor and autologous stem-cell transplantation support as first-line therapy in high risk diffuse large cell lymphoma. J Clin Oncol 1997; 15: 491-8. (P2/50)
   Google Scholar
• Reyes F, Lepage E, Morel P, et al. Failure of first line inductive high-dose chemotherapy in poor-risk patients with aggressive lymphoma: Updated results of the randomised LNH 93-3-study. Blood 1997; 90 (Suppl I) Abstr 594. (C3/ 370)
   Google Scholar
• Kaiser U, Uebelacker I, Havemann K on behalf of the German High Grade Lymphoma Study Group: High dose chemotherapy with autologous stem cell transplantation in high grade NHL: first analysis of a randomised multicenter study. Bone Marrow Transplant 1998; 21 (Suppl 1): Abstr 177. (C3/312)
   Google Scholar
• Kaiser U, Uebelacker I, Birkmann J, et al. High dose therapy with autologous stem cell transplantation in aggres-sive NHL: Results of a randomized multicenter study. Blood 1999; (Suppl): Abstr 2716. (C3/312)
   Google Scholar
• Gianni AM, Bregni M, Siena S, et al. High-dose chemother-apy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 1997; 336: 1290-7. (C2/101)
   Google Scholar
• Hag R, Sawka CA, Franssen E, et al. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994; 12: 1074-84. (02)
   Google Scholar
• Philip T, Hartman O, Biron P. High dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1118-24. (P3/17)
   Google Scholar
• Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow trans-plantation vs dexamethasone, cisplatin and cytarbine in ag-gressive non-Hodgkin's lymphoma (NHL) with partial response to front-line chemotherapy. A prospective ran-domised Italian multicenter trial. J Clin Oncol 1996; 14: 534–42. (C2/286, C3/49 in PR randomised to high-dose)
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. High-dose ther-apy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; Suppl 1: 5–8. (R2/ 94)
   Google Scholar
• Verdonck LF, van Patten WL, Hagenbeek A, et al. Com-parison of CHOP chemotherapy with autologous bone mar-row transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New Engl J Med 1995; 332: 1045-51. (C3/69)
   Google Scholar
• Gribben JG, Vaughan Hudson B, Linch DC. The potential value of very intensive therapy with autologous bone mar-row rescue in the treatment of malignant lymphomas. Haematol Oncol 1987; 5: 281-93. (R2/50)
   Google Scholar
• Fielding AK, Philip T, Carella A, et al. Autologous bone marrow transplantation for lymphomas - A 15-year Eu-ropean bone marrow transplant registry (EBMT) experience of 3 325 patients. Proc Am Soc Hematol, Blood 1994; 84 Abstr 2130. (R1/3325)
   Google Scholar
• Bosly A, Coiffier B, Gisselbrecht C, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-94 regimen. J Clin Oncol 1992; 10: 1615-23. (R2/244)
   Google Scholar
• Attal M, Canal P, Schlaifer D, et al. Escalating doses of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma under-going autologous bone marrow transplantation. J Clin Oncol 1994; 12: 141-8. (P3/20)
   Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540–5. (C2 /215, 109 chemosensitive randomised)
   PubMed Web of Science ®Google Scholar
• Bosly A, Sonet A, Salles G, et al. Superiority of late over early intensification in relapsing/refractory aggressive lymphoma: a randomised study from the GELA: LNH RP 93. Proc Eur Bone Marrrow Transpl 1998; 585: Abstr 170. (C3/66)
   Google Scholar
• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-8. (P3/100)
   Google Scholar
• Vose J. High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma. Ann Oncol 1998; 9 (Suppl 1): 1–3. (L 1)
   Google Scholar
• Vose J, Rowlings P, Lazarus H, et al. Multivariate analysis of autotransplant for patients with aggressive non-Hodgkin's lymphoma failing primary induction therapy. Blood 1997; 90: (Suppl 1): Abstr 594. (R2/221)
   Google Scholar
• d'Amore, Brincker H, Christensen BE. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Ann Oncol 1992; 3: 379-86. (R1/602)
   Google Scholar
• Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: Population-based results in the Netherlands. Ann Oncol 1998; 9: 1219-27. (R1/1168)
   Google Scholar
• Sonnenveld P, de Ridder M, van der Lelie H, et al. Compari-son of doxorubicin and itoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-9. (C2/145)
   Google Scholar
• Björkholm M, Osby E, Hagberg H, et al. Randomized trial of r-metHu granulocyte colony stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Blood 1999; (Suppl): Abstr 2665. (C3/458)
   Google Scholar
• Coiffier B. What treatment for elderly patients with aggres-sive lymphoma. Ann Oncol 1994; 5: 873-5. (L2)
   PubMedGoogle Scholar
• Martelli M, Guglielmi C, Coluzzi S, et al. P-VAPEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2362-9. (P2/60)
   Google Scholar
• Young WA, Greco FA, Greer JP, et al. Aggressive non-Hodgkin's lymphoma in the elderly: an effective well-toler-ated treatment regimen containing extended-schedule etoposide. J Natl Cancer Inst 1994; 86: 146-7. (P3/31)
   Google Scholar